Cancer
Reuben Harris, PhD, to chair Department of Biochemistry and Structural Biology
March 17, 2022
Cancer and virology researcher Reuben Harris, PhD, has been named chairman of the Department of Biochemistry and Structural Biology at UT Health San Antonio. The department is in the Joe R. and Teresa Lozano Long School of Medicine. Dr. Harris, a professor with tenure, will assume his duties effective April 11, 2022, announced Robert Hromas, […]
Mays Cancer Center researcher and SignalRx earn NCI business grants to develop drugs for first-in-human clinical trials
March 10, 2022
An internationally recognized physician-scientist of Mays Cancer Center at UT Health San Antonio, together with SignalRx Pharmaceuticals Inc., have secured two National Cancer Institute business grants to further develop drugs on a pathway to first-in-human cancer clinical trials. The clinical translational researcher, Daruka Mahadevan, MD, PhD, division chief of hematology and medical oncology at UT […]
Mays Cancer Center researcher and SignalRx earn NCI business grants to develop drugs for first-in-human clinical trials
March 10, 2022
Contact: Steven Lee, 210-450-3823, lees22@uthscsa.edu SAN ANTONIO – An internationally recognized physician-scientist of Mays Cancer Center at UT Health San Antonio together with SignalRx Pharmaceuticals Inc. have secured two National Cancer Institute business grants to further develop drugs on a pathway to first-in-human cancer clinical trials. The clinical translational researcher, Daruka Mahadevan, MD, PhD, division […]
Mays Cancer Center studies help spur leukemia drug’s approval
March 3, 2022
The FDA has approved pacritinib for myelofibrosis patients with low platelet counts. Investigators at the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, played a lead role in gaining U.S. Food and Drug Administration approval of pacritinib to treat the chronic leukemia known as myelofibrosis. The FDA granted accelerated approval of the […]
Yahoo Finance: NCCN Clinical Practice Guidelines in Oncology Update Recommends BESREMi® for the Treatment of Polycythemia Vera
March 2, 2022
Dr. Ruben Mesa, Mays Cancer Center, is quoted in this article. Read More
Cancer Network: Mesa Discusses Importance of Pacritinib Accelerated Approval for Myelofibrosis With Severe Thrombocytopenia
March 1, 2022
Dr. Ruben Mesa, executive director of the Mays Cancer Center, gives video comments about FDA approval of a new drug for a chronic leukemia. Watch Video